TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Although brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has been used in some advanced cases of MF and PTCL, it was not pursued in our patient due to the subsequent loss of CD30 expression after transformation, as well as comorbidities and suspected CNS involvement.